Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Mental Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1845310

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1845310

Psychedelic Drugs Market - Global Psychedelic Drugs Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product Type, By Therapeutic Indication, By Route of Administration, By Origin, By Geographic Coverage and By Company)

PUBLISHED:
PAGES: 189 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global Psychedelic Drugs Market is witnessing significant momentum, valued at approximately USD 4.1 billion in 2025 and projected to reach around USD 9.5 billion by 2032, growing at a robust CAGR of 12.9%. This growth is largely driven by expanding research in mental health disorders, evolving regulatory frameworks, and increasing investment in psychedelic-assisted therapies across key global markets. Psychedelics are emerging as a transformative category in modern psychiatry, targeting conditions where traditional therapies have shown limited efficacy.

Market Insights

Growing awareness about treatment-resistant depression, PTSD, and addiction disorders has created an urgent demand for novel therapeutic solutions. Psychedelic compounds such as psilocybin, ketamine, and MDMA are demonstrating high clinical success rates, especially in controlled and monitored settings. Global regulatory agencies are moving towards approval frameworks for these therapies, while pharmaceutical companies are investing heavily in R&D collaborations and clinical trials.

Rising acceptance from mental health practitioners and institutions, along with growing patient advocacy, underscores the market's evolving perception from stigma to legitimacy. Academic institutions and startups are also contributing to clinical advancements, enhancing accessibility and driving innovation.

Market Drivers

  • Rising Prevalence of Mental Health Disorders: Increasing rates of anxiety, depression, and PTSD worldwide are fueling interest in psychedelic-based therapies as viable alternatives to conventional antidepressants.
  • Supportive Regulatory Approvals: Accelerating FDA and EMA approvals for trials on psilocybin and MDMA-based treatments are broadening therapeutic horizons.
  • Growing Clinical Validation: Multiple clinical studies demonstrate the long-term efficacy and safety of psychedelic-assisted psychotherapy, driving confidence among physicians and investors alike.
  • Increased R&D and Strategic Collaborations: Pharmaceutical leaders and biotech startups are forming alliances to expand psychedelic drug portfolios, optimizing formulation and delivery mechanisms.
  • Shift Toward Personalized Mental Healthcare: Psychedelics align with the growing trend of precision medicine, providing individualized treatment pathways based on patient neurochemistry and psychological needs.

Business Opportunity

The market offers extensive growth potential across both developed and emerging regions. Pharmaceutical and biotech companies are focusing on patent development and innovative formulations to gain a competitive edge. Investment opportunities are expanding beyond traditional pharma, with venture capitalists and institutional investors actively funding psychedelic therapy centers and research startups.

Digital health platforms and telepsychiatry are also opening new frontiers for integrating psychedelic-assisted therapy into remote care frameworks. Moreover, decriminalization and legalization movements in regions such as North America and parts of Europe are creating a conducive ecosystem for market expansion and commercialization.

Regional Analysis

North America remains the leading region, supported by a strong clinical trial pipeline, favorable legislative initiatives, and a growing number of mental health treatment centers incorporating psychedelic-assisted therapies. The U.S. continues to dominate due to progressive regulatory reforms and funding initiatives aimed at mental wellness innovation.

Europe follows closely, led by the U.K., Germany, and the Netherlands, where psilocybin and MDMA research programs are gaining substantial government and private backing.

Asia Pacific is emerging as a high-growth region, driven by rising awareness, expanding healthcare infrastructure, and increasing participation in international clinical collaborations. Latin America and the Middle East & Africa are in the early stages but show potential as research hubs and low-cost clinical trial destinations.

Key Players

The global Psychedelic Drugs Market features several established pharmaceutical companies and emerging biotech innovators actively advancing research, clinical trials, and commercialization. Prominent players include:

  • Johnson & Johnson
  • Jazz Pharmaceuticals
  • COMPASS Pathways
  • MindMed
  • Cybin Inc.
  • Psygen Labs
  • Atai Life Science
  • CaaMTech
  • Mydecine Innovations Group
  • Entheon Biomedical
  • PharmaThera Biotech
  • Seelos Therapeutics

These companies are investing in advanced formulation techniques, fast-track clinical trials, and collaborations with mental health institutions to accelerate commercialization timelines and regulatory approvals.

Segmentation

By Product Type

  • DMT
  • Ketamine
  • LSD
  • MDMA
  • Mescaline
  • Psilocybin

By Therapeutic Indication

  • Depression & Anxiety
  • PTSD
  • Drug & Alcohol Dependence

By Route of Administration

  • Oral
  • Intranasal
  • Intravenous

By Origin

  • Natural
  • Synthetic

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Psychedelic Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Fiver Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2024-2032
    • 2.9.2. Price Impact Factors

3. Global Psychedelic Drugs Market Outlook, 2019 - 2032

  • 3.1. Global Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
    • 3.1.1. DMT
    • 3.1.2. Ketamine
    • 3.1.3. LSD
    • 3.1.4. MDMA
    • 3.1.5. Mescaline
    • 3.1.6. Psilocybin
    • 3.1.7. Misc.
  • 3.2. Global Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
    • 3.2.1. Depression & Anxiety
    • 3.2.2. PTSD
    • 3.2.3. Drug & Alcohol dependence
    • 3.2.4. Misc.
  • 3.3. Global Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
    • 3.3.1. Oral
    • 3.3.2. Intranasal
    • 3.3.3. Intravenous
    • 3.3.4. Misc.
  • 3.4. Global Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
    • 3.4.1. Natural
    • 3.4.2. Synthetic
  • 3.5. Global Psychedelic Drugs Market Outlook, by Region, Value (US$ Bn), 2019-2032
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Psychedelic Drugs Market Outlook, 2019 - 2032

  • 4.1. North America Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
    • 4.1.1. DMT
    • 4.1.2. Ketamine
    • 4.1.3. LSD
    • 4.1.4. MDMA
    • 4.1.5. Mescaline
    • 4.1.6. Psilocybin
    • 4.1.7. Misc.
  • 4.2. North America Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
    • 4.2.1. Depression & Anxiety
    • 4.2.2. PTSD
    • 4.2.3. Drug & Alcohol dependence
    • 4.2.4. Misc.
  • 4.3. North America Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
    • 4.3.1. Oral
    • 4.3.2. Intranasal
    • 4.3.3. Intravenous
    • 4.3.4. Misc.
  • 4.4. North America Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
    • 4.4.1. Natural
    • 4.4.2. Synthetic
  • 4.5. North America Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
    • 4.5.1. U.S. Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 4.5.2. U.S. Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 4.5.3. U.S. Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 4.5.4. U.S. Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 4.5.5. Canada Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 4.5.6. Canada Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 4.5.7. Canada Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 4.5.8. Canada Psychedelic Drugs Market Outlook, by Origin, 2019-2032
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Psychedelic Drugs Market Outlook, 2019 - 2032

  • 5.1. Europe Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
    • 5.1.1. DMT
    • 5.1.2. Ketamine
    • 5.1.3. LSD
    • 5.1.4. MDMA
    • 5.1.5. Mescaline
    • 5.1.6. Psilocybin
    • 5.1.7. Misc.
  • 5.2. Europe Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
    • 5.2.1. Depression & Anxiety
    • 5.2.2. PTSD
    • 5.2.3. Drug & Alcohol dependence
    • 5.2.4. Misc.
  • 5.3. Europe Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
    • 5.3.1. Oral
    • 5.3.2. Intranasal
    • 5.3.3. Intravenous
    • 5.3.4. Misc.
  • 5.4. Europe Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
    • 5.4.1. Natural
    • 5.4.2. Synthetic
  • 5.5. Europe Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
    • 5.5.1. Germany Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 5.5.2. Germany Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 5.5.3. Germany Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 5.5.4. Germany Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 5.5.5. Italy Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 5.5.6. Italy Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 5.5.7. Italy Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 5.5.8. Italy Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 5.5.9. France Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 5.5.10. France Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 5.5.11. France Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 5.5.12. France Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 5.5.13. U.K. Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 5.5.14. U.K. Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 5.5.15. U.K. Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 5.5.16. U.K. Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 5.5.17. Spain Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 5.5.18. Spain Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 5.5.19. Spain Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 5.5.20. Spain Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 5.5.21. Russia Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 5.5.22. Russia Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 5.5.23. Russia Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 5.5.24. Russia Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 5.5.25. Rest of Europe Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 5.5.26. Rest of Europe Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 5.5.27. Rest of Europe Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 5.5.28. Rest of Europe Psychedelic Drugs Market Outlook, by Origin, 2019-2032
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Psychedelic Drugs Market Outlook, 2019 - 2032

  • 6.1. Asia Pacific Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
    • 6.1.1. DMT
    • 6.1.2. Ketamine
    • 6.1.3. LSD
    • 6.1.4. MDMA
    • 6.1.5. Mescaline
    • 6.1.6. Psilocybin
    • 6.1.7. Misc.
  • 6.2. Asia Pacific Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
    • 6.2.1. Depression & Anxiety
    • 6.2.2. PTSD
    • 6.2.3. Drug & Alcohol dependence
    • 6.2.4. Misc.
  • 6.3. Asia Pacific Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
    • 6.3.1. Oral
    • 6.3.2. Intranasal
    • 6.3.3. Intravenous
    • 6.3.4. Misc.
  • 6.4. Asia Pacific Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
    • 6.4.1. Natural
    • 6.4.2. Synthetic
  • 6.5. Asia Pacific Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
    • 6.5.1. China Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 6.5.2. China Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 6.5.3. China Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 6.5.4. China Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 6.5.5. Japan Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 6.5.6. Japan Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 6.5.7. Japan Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 6.5.8. Japan Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 6.5.9. South Korea Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 6.5.10. South Korea Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 6.5.11. South Korea Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 6.5.12. South Korea Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 6.5.13. India Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 6.5.14. India Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 6.5.15. India Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 6.5.16. India Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 6.5.17. Southeast Asia Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 6.5.18. Southeast Asia Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 6.5.19. Southeast Asia Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 6.5.20. Southeast Asia Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 6.5.21. Rest of SAO Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 6.5.22. Rest of SAO Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 6.5.23. Rest of SAO Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 6.5.24. Rest of SAO Psychedelic Drugs Market Outlook, by Origin, 2019-2032
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Psychedelic Drugs Market Outlook, 2019 - 2032

  • 7.1. Latin America Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
    • 7.1.1. DMT
    • 7.1.2. Ketamine
    • 7.1.3. LSD
    • 7.1.4. MDMA
    • 7.1.5. Mescaline
    • 7.1.6. Psilocybin
    • 7.1.7. Misc.
  • 7.2. Latin America Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
    • 7.2.1. Depression & Anxiety
    • 7.2.2. PTSD
    • 7.2.3. Drug & Alcohol dependence
    • 7.2.4. Misc.
  • 7.3. Latin America Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
    • 7.3.1. Oral
    • 7.3.2. Intranasal
    • 7.3.3. Intravenous
    • 7.3.4. Misc.
  • 7.4. Latin America Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
    • 7.4.1. Natural
    • 7.4.2. Synthetic
  • 7.5. Latin America Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
    • 7.5.1. Brazil Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 7.5.2. Brazil Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 7.5.3. Brazil Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 7.5.4. Brazil Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 7.5.5. Mexico Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 7.5.6. Mexico Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 7.5.7. Mexico Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 7.5.8. Mexico Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 7.5.9. Argentina Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 7.5.10. Argentina Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 7.5.11. Argentina Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 7.5.12. Argentina Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 7.5.13. Rest of LATAM Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 7.5.14. Rest of LATAM Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 7.5.15. Rest of LATAM Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 7.5.16. Rest of LATAM Psychedelic Drugs Market Outlook, by Origin, 2019-2032
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Psychedelic Drugs Market Outlook, 2019 - 2032

  • 8.1. Middle East & Africa Psychedelic Drugs Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
    • 8.1.1. DMT
    • 8.1.2. Ketamine
    • 8.1.3. LSD
    • 8.1.4. MDMA
    • 8.1.5. Mescaline
    • 8.1.6. Psilocybin
    • 8.1.7. Misc.
  • 8.2. Middle East & Africa Psychedelic Drugs Market Outlook, by Therapeutic Indication, Value (US$ Bn), 2019-2032
    • 8.2.1. Depression & Anxiety
    • 8.2.2. PTSD
    • 8.2.3. Drug & Alcohol dependence
    • 8.2.4. Misc.
  • 8.3. Middle East & Africa Psychedelic Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
    • 8.3.1. Oral
    • 8.3.2. Intranasal
    • 8.3.3. Intravenous
    • 8.3.4. Misc.
  • 8.4. Middle East & Africa Psychedelic Drugs Market Outlook, by Origin, Value (US$ Bn), 2019-2032
    • 8.4.1. Natural
    • 8.4.2. Synthetic
  • 8.5. Middle East & Africa Psychedelic Drugs Market Outlook, by Country, Value (US$ Bn), 2019-2032
    • 8.5.1. GCC Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 8.5.2. GCC Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 8.5.3. GCC Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 8.5.4. GCC Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 8.5.5. South Africa Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 8.5.6. South Africa Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 8.5.7. South Africa Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 8.5.8. South Africa Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 8.5.9. Egypt Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 8.5.10. Egypt Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 8.5.11. Egypt Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 8.5.12. Egypt Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 8.5.13. Nigeria Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 8.5.14. Nigeria Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 8.5.15. Nigeria Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 8.5.16. Nigeria Psychedelic Drugs Market Outlook, by Origin, 2019-2032
    • 8.5.17. Rest of Middle East Psychedelic Drugs Market Outlook, by Product Type, 2019-2032
    • 8.5.18. Rest of Middle East Psychedelic Drugs Market Outlook, by Therapeutic Indication, 2019-2032
    • 8.5.19. Rest of Middle East Psychedelic Drugs Market Outlook, by Route of Administration, 2019-2032
    • 8.5.20. Rest of Middle East Psychedelic Drugs Market Outlook, by Origin, 2019-2032
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2024
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Johnson & Johnson
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Jazz Pharmaceuticals
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Developments
    • 9.4.3. COMPASS Pathways
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Developments
    • 9.4.4. MindMed
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Developments
    • 9.4.5. Cybin Inc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Developments
    • 9.4.6. Psygen Labs
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Developments
    • 9.4.7. Atai Life Science
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Developments
    • 9.4.8. CaaMTech
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Developments
    • 9.4.9. Mydecine Innovations Group
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Developments
    • 9.4.10. Entheon Biomedical
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Developments

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!